Aza–ven combination outperforms standard care in AML patients eligible for intensive chemotherapy
In a new trial, patients newly diagnosed with acute myeloid leukemia (AML) fared significantly better with a combined regimen of azacitidine and venetoclax compared with conventional induction chemotherapy. The azacitidine–venetoclax ...
Dec 8, 2025
0
0








